Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL682 (Amodiaquin, Amodiaquine, Amodiaquinum, GNF-Pf-5648, NSC-13453, SJ000110703, Sunoquine) |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
Amyloid-beta A4 protein in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2487] [UniProtKB: P05067] | ||||||||
ChEMBL | Modulation of human wild-type APP695 expressed in SH-SY5Y cells assessed as inhibition of amyloid beta (1 to 42 residues) production measured after 24 hrs by ELISA | B | 5.27 | pIC50 | 5400 | nM | IC50 | Bioorg Med Chem (2018) 26: 2151-2164 [PMID:29559198] |
ChEMBL | Modulation of human wild-type APP695 expressed in SH-SY5Y cells assessed as inhibition of amyloid beta (1 to 40 residues) production measured after 24 hrs | B | 5.4 | pIC50 | 4000 | nM | IC50 | Bioorg Med Chem (2018) 26: 2151-2164 [PMID:29559198] |
Hemozoin in Plasmodium falciparum (target type: MACROMOLECULE) [ChEMBL: CHEMBL613898] | ||||||||
ChEMBL | Inhibition of beta-hematin | B | 4.68 | pIC50 | 21000 | nM | IC50 | J Med Chem (2016) 59: 6512-6530 [PMID:27299916] |
ChEMBL | Inhibition of beta-hematin formation assessed as reduction in hemozoin formation incubated for 5 hrs by NP40 detergent-based assay | B | 4.89 | pIC50 | 13000 | nM | IC50 | Medchemcomm (2019) 10: 450-455 [PMID:31015908] |
ChEMBL | Inhibition of Beta-hematin in Plasmodium falciparum NF54 assessed as hemozoin formation after 36 hrs by flow cytometry analysis | B | 5 | pIC50 | 10000 | nM | IC50 | J Med Chem (2022) 65: 16695-16715 [PMID:36507890] |
ChEMBL | Inhibition of Beta-hematin assessed as bis-pyridyl-Fe(III)PPIX complex formation incubated for 5 hrs by NP40 detergent-mediated colorimetric assay | B | 5.07 | pIC50 | 8600 | nM | IC50 | J Med Chem (2021) 64: 2739-2761 [PMID:33620219] |
Nuclear receptor related 1/Nuclear receptor subfamily 4 group A member 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5002] [GtoPdb: 630] [UniProtKB: P43354] | ||||||||
ChEMBL | Agonist activity at Gal4-fused human Nurr1 LBD expressed in HEK293T cells co-expressing firefly luciferase assessed as luciferase activity in presence of 5-(Pyridin-3-yl)-1-methylindole-3-carboxylic Acid Methyl Ester by hybrid reporter gene assay | B | 4.09 | pEC50 | 82000 | nM | EC50 | J Med Chem (2021) 64: 15126-15140 [PMID:34633810] |
ChEMBL | Agonist activity at Gal4-fused human Nurr1 LBD expressed in HEK293T cells co-expressing firefly luciferase assessed as luciferase activity by hybrid reporter gene assay | B | 4.39 | pEC50 | 41000 | nM | EC50 | J Med Chem (2021) 64: 15126-15140 [PMID:34633810] |
ChEMBL | Agonist activity at Gal4-fused human Nurr1 LBD expressed in HEK293T cells co-expressing firefly luciferase assessed as luciferase activity incubated for 12 to 14 hrs by hybrid reporter gene assay | B | 4.44 | pEC50 | 36000 | nM | EC50 | J Med Chem (2021) 64: 2659-2668 [PMID:33629841] |
ChEMBL | Agonist activity at Nurr1 ligand binding domain (unknown origin) measured by Gal4-based reporter gene assay | B | 4.7 | pEC50 | 20000 | nM | EC50 | J Med Chem (2022) 65: 9548-9563 [PMID:35797147] |
Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364] | ||||||||
ChEMBL | Antimalarial activity against Plasmodium falciparum 3D7 asexual forms incubated for 72 hrs by luminescence method | F | 4.75 | pIC50 | 17900 | nM | IC50 | Eur J Med Chem (2020) 188: 111983-111983 [PMID:31911292] |
ChEMBL | Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 infected in human erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay | F | 8.1 | pIC50 | 8 | nM | IC50 | Bioorg Med Chem (2015) 23: 5419-5432 [PMID:26264839] |
ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human A+ erythrocytes assessed as inhibition of [3H]-hypoxanthine incorporation after 42 hrs by beta counting method | F | 8.22 | pIC50 | 6 | nM | IC50 | Eur J Med Chem (2017) 126: 72-83 [PMID:27744189] |
ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human A+ erythrocytes after 48 hrs by SYBR Green based fluorescence assay | F | 8.22 | pIC50 | 6 | nM | IC50 | Eur J Med Chem (2017) 126: 72-83 [PMID:27744189] |
ChEMBL | Antimalarial activity against chloroquine-resistant and mefloquine-sensitive Plasmodium falciparum W2 ring stage form infected in human erythrocytes by spectrophotometric analysis | F | 8.22 | pIC50 | 6 | nM | IC50 | Bioorg Med Chem (2019) 27: 1002-1008 [PMID:30737133] |
ChEMBL | Antiplasmodial activity against Plasmodium falciparum W2 infected in human erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay | F | 8.3 | pIC50 | 5 | nM | IC50 | Bioorg Med Chem (2015) 23: 5419-5432 [PMID:26264839] |
ChEMBL | Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in human erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay | F | 8.4 | pIC50 | 4 | nM | IC50 | Bioorg Med Chem (2015) 23: 5419-5432 [PMID:26264839] |
ChEMBL | Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in human erythrocyte assessed as growth inhibition by SYBR Green-1 assay | F | 7.91 | pEC50 | 12.3 | nM | EC50 | Eur J Med Chem (2015) 102: 320-333 [PMID:26295174] |
ChEMBL | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocyte assessed as growth inhibition by SYBR Green-1 assay | F | 8.23 | pEC50 | 5.85 | nM | EC50 | Eur J Med Chem (2015) 102: 320-333 [PMID:26295174] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]